Should I Sell Moderna Shares?
Moderna (NASDAQ: MRNA) is a white-hot COVID-19 stock just now. Onlookers have high hopes for mRNA-1273, the company's SARS-CoV-2 vaccine candidate, which is progressing rapidly through the development process. It's now well into phase 2 clinical testing, and the company has been given FDA approval to start a phase 3 study next month.
Many investors, it seems, are betting that the vaccine candidate will not only be successful, but successful early enough to garner a significant first-mover advantage. Given that nearly every rational human being on Earth will want and need vaccination against COVID-19, that market is set to be unimaginably massive.
It's an exciting possibility for Moderna, but investors have to bear a few things in mind once the dream wears off.
Source Fool.com
